Sfoglia per Rivista
Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project
2019 E. Santagostino, A. Riva, S. Cesaro, S. Esposito, D. Matino, R.I. Mazzucchelli, A.C. Molinari, R. Mura, L.D. Notarangelo, A. Tagliaferri, G. Di Minno, M. Clerici
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors
2006 J. Astermark, M. Morado, A. Rocino, H.M. van den Berg, M. von Depka, A. Gringeri, L. Mantovani, R.P. Garrido, M. Schiavoni, A. Villar, J. Windyga, EHTSB
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
2007 A. Astermark, A. Rocino, M. Von Depka, H.M. Van Den Berg, A. Gringeri, L.G. Mantovani, M. Morado, R.P. Garrido, M. Schiavoni, A. Villar, J. Windyga
Delivery of AAV-based gene therapy through haemophilia centres—A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC
2021 W. Miesbach, P. Chowdary, M. Coppens, D.P. Hart, V. Jimenez-Yuste, R. Klamroth, M. Makris, D. Noone, F. Peyvandi
Desmopressin : an historical introduction
2008 P.M. Mannucci
Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia : a discrete choice experiment
2005 G. Tagariello, R. Musso, G. Piseddu, A. Rocino, G. Rodorigo, G. Rossetti, F.A. Scaraggi, P. Schinco, A. Tagliaferri, R. Targhetta, M. Morfini, V.T. Lombardo, E. Zanon, M. Schiavoni, L. Bizzoni, A. Iorio, P. Iannaccaro, E. Santagostino, M. D'Inca, D. Bertuzzo, G. Feola, A. Coppola, L. Contino, G. Castaman, G. Mancuso, E. Boeri, A. Dragani, A. Billio, F. Baudo, G. Barillari, A. Gringeri, M. Villa, L. Scalone, P.M. Mannucci, M.S. Monzini, L.G. Mantovani, B. Caputo, G. Delios
Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation
2018 M.T. Pagliari, L. Baronciani, F. Stufano, P. Colpani, S.M. Siboni, F. Payvandi
Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe ?
2014 B. O'Mahony, F. Peyvandi, A. Bok
The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients
2022 M.T. Pagliari, L. Baronciani, C. Cordiglieri, P. Colpani, G. Cozzi, S.M. Siboni, F. Peyvandi
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
2019 J. Oldenburg, J.N. Mahlangu, W. Bujan, P. Trask, M.U. Callaghan, G. Young, E. Asikanius, F. Peyvandi, E. Santagostino, R. Kruse-Jarres, C. Negrier, C. Kessler, X. Jin, J. Windyga, M. Shima, S. von Mackensen
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs
2008 A. Tagliaferri, M. Franchini, A. Coppola, G.F. Rivolta, C. Santoro, G. Rossetti, G. Feola, E. Zanon, A. Dragani, P. Iannaccaro, P. Radossi, P.M. Mannucci
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate : results from an Italian prospective observational study in patients with von Willebrand disease
2013 G. Castaman, A. Coppola, E. Zanon, E. Boeri, M. Musso, S. Siragusa, A.B. Federici, G. Mancuso, G. Barillari, C. Biasoli, G. Feola, M. Franchini, S. Moratelli, G. Gamba, P. Schinco, L. Valdrè, A. Dragani, G. Mazzucconi, A. Tagliaferri, M. Morfini
Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures
2017 A. Srivastava, M. Serban, S. Werner, B.A. Schwartz, C.M. Kessler, S. Alkindi, S.J. Apte, G. Castaman, J.C. Gill, A. Hellmann, K. Kavakli, P.A. Kouides, P. Kuriakose, T. Lissitchkov, M. Alice, J. Mahlangu, M. Morfini, E.J. Neufeld, F. Peyvandi, M. Reding, N.I. Rodriguez, C. Ross, L. Rusen, A. Shapiro, V. Uscatescu, J. Windyga, B. Zulfikar
Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency
2020 C. Djambas Khayat, S. Lohade, F. D'Souza, L.G. Shamanur, O.R. Zekavat, I. Kruzhkova, B. Schwartz, C. Solomon, S. Knaub, F. Peyvandi
Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease : results of an Italian cohort study on 120 patients characterized by bleeding severity score
2010 A.B. Federici, G. Barillari, E. Zanon, M.G. Mazzucconi, R. Musso, R. Targhetta, P.M. Mannucci
Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran
2012 M. Karimi, A. Vafafar, S. Haghpanah, M. Payandeh, P. Eshghi, H. Hoofar, A. Afrasiabi, J. Gerdabi, R. Ardeshiri, M. Menegatti, F. Peyvandi
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency
2016 S.K. Austin, K. Kavakli, M. Norton, F. Peyvandi, A. Shapiro
Emerging and re-emerging infections at the turn of the millennium
2010 A.R. Zanetti, A. Zappa
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome
2008 P. Collins, U. Budde, J.H. Rand, A.B. Federici, C.M. Kessler
European principles of haemophilia care
2008 B. T. Colvin, J. Astermark, K. Fischer, A. Gringeri, R. Lassila, W. Schramm, A. Thomas, J. Ingerslev, Inter Disciplinary Working Group
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile